[{"arm_notes": "", "treatment_id": null, "treatment_name": "Eligible participants were allocated at a 1:1:1 ratio to receive orally (or via nasogastric tube in case of orotracheal intubation) either: A) chloroquine difosfate (450mg; twice in day 0; and once daily from day 1 to day 4; total dose 2.7g); or B) hydroxychloroquine sulfate (400mg twice in day 0; and once daily from day 1 to day 4; total dose 2.4g); or C) ivermectine (14mg once at day 0 + 1 placebo tablet at day 0; and once daily from day 1 to day 2; + 1 placebo tablet daily from day 3 to 4; total dose 42mg). For participants with body weight under 55kg; ivermectine dose was adjusted to 10mg each dose. Investigational products were produced blindly by an independent pharmacy. Placebo tablets were also produced by the same pharmacy in order to standardize treatment and blinding of research team and participants.;Drug;D002738;D006886;D02.540.576.500.997", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 279, "treatment_name": "Chloroquine", "treatment_type": "Antimalarials", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 607, "treatment_name": "Hydroxychloroquine", "treatment_type": "Antimalarials", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 693, "treatment_name": "Ivermectin", "treatment_type": "Antiparasitics", "pharmacological_treatment": "Pharmacological treatment"}]

[{"arm_notes": "", "treatment_id": null, "treatment_name": "Eligible participants were allocated at a 1:1:1 ratio to receive orally (or via nasogastric tube in case of orotracheal intubation) either: A) chloroquine difosfate (450mg; twice in day 0; and once daily from day 1 to day 4; total dose 2.7g); or B) hydroxychloroquine sulfate (400mg twice in day 0; and once daily from day 1 to day 4; total dose 2.4g); or C) ivermectine (14mg once at day 0 + 1 placebo tablet at day 0; and once daily from day 1 to day 2; + 1 placebo tablet daily from day 3 to 4; total dose 42mg). For participants with body weight under 55kg; ivermectine dose was adjusted to 10mg each dose. Investigational products were produced blindly by an independent pharmacy. Placebo tablets were also produced by the same pharmacy in order to standardize treatment and blinding of research team and participants.;Drug;Chloroquine;hydroxychloroquine;ivermectin", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]